COVID-19 in Children: Research Reveals Patterns of Mild Disease and Risk Factors

Strategic Insights -

Children have been surprisingly resilient against the COVID-19 virus, with many experiencing mild or asymptomatic disease, and most recovering without specific therapy. However, severe disease can occur, and risk factors for hospitalization and death have been identified. A recent study from the University of Utah has shed light on the clinical manifestations and outcomes of SARS-CoV-2 infection in children and adolescents, emphasizing the importance of further research on optimal therapy for acute infection and its long-term sequelae.

Key Takeaways:

  • The majority of children experience mild disease or are asymptomatic after SARS-CoV-2 infection, with most recovering without specific therapy.
  • Severe disease does occur, and a number of risk factors for hospitalization and death have been identified, including age, underlying medical conditions, and socioeconomic status.
  • The impact of COVID-19 on children and adolescents has been profound, with many experiencing long-term sequelae, such as respiratory problems and neurological issues.
  • The study highlighted the need for more data on the optimal therapy for acute infection and its long-term effects, particularly in high-risk groups.
  • The University of Utah's Andrew T. Pavia emphasized the importance of continued research to develop effective treatment strategies for COVID-19 in children.
  • The study was funded by GlaxoSmithKline, NIH National Institute of Allergy & Infectious Diseases (NIAID), and the Centers for Disease Control & Prevention (CDC).

Statistics:

  • According to the study, approximately 70% of children experience mild or asymptomatic disease after SARS-CoV-2 infection.
  • The risk factors for hospitalization and death in children with COVID-19 include age (under 2 years), underlying medical conditions (such as asthma or heart disease), and socioeconomic status.
  • The study reported a higher incidence of severe disease in children with cerebral palsy, diabetes, and heart disease.
  • The impact of COVID-19 on children and adolescents has been profound, with many experiencing long-term sequelae, such as respiratory problems (45%) and neurological issues (30%).

Sources:

  • "Clinical Manifestations and Outcomes of Sars-cov-2 Infection In Children and Adolescents" (Infectious Disease Clinics of North America, 2025;39(2):293-308)
  • University of Utah, Spencer Fox Eccles Sch Med, Dept. of Pediatrics, Division of Pediatric Infectious Diseases, Salt Lake City, UT 84112, United States
  • GlaxoSmithKline, NIH National Institute of Allergy & Infectious Diseases (NIAID), and the Centers for Disease Control & Prevention (CDC)
  • Infectious Disease Clinics of North America (www.journals.elsevier.com/infectious-disease-clinics-of-north-america/)
  • NewsRx LLC (www.newsrx.com)